Morphic to Participate in RBC Capital Markets Global Healthcare Conference
09 Maio 2024 - 5:05PM
Morphic Therapeutic (Nasdaq: MORF), a biotechnology company
developing a new generation of oral integrin therapies for the
treatment of serious chronic diseases, today announced that Dr.
Marc Schegerin, COO and CFO, will take part in a fireside chat at
the 2024 RBC Capital Markets Global Healthcare Conference on
Wednesday, May 15th, at 9:00 AM ET.
A live webcast of the panel discussion and
fireside chat at the RBC Global Healthcare Conference will be
available on the Investor section of Morphic’s website
at www.morphictx.com. An archived replay will be available on
the company’s website following the conference.
About Morphic
TherapeuticMorphic Therapeutic is a biopharmaceutical
company developing a portfolio of oral integrin therapies for the
treatment of serious chronic diseases, including autoimmune,
cardiovascular, and metabolic diseases, fibrosis, and cancer.
Morphic is also advancing its pipeline and discovery activities in
collaboration with Schrödinger using its proprietary MInT
technology platform which leverages the Company’s unique
understanding of integrin structure and biology. For more
information, visit www.morphictx.com.
ContactsMorphic TherapeuticChris
Erdmanchris.erdman@morphictx.com617.686.1718
Morphic (NASDAQ:MORF)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Morphic (NASDAQ:MORF)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024